Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

102.61 +0.11 (+0.11%)

Streaming Delayed Price Updated: 2:59 PM EST, Feb 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,054,632
Open	102.52
Bid (Size)	102.61 (200)
Ask (Size)	102.62 (600)
Prev. Close	102.50
Today's Range	102.48 - 102.70
52wk Range	38.81 - 102.66
Shares Outstanding	171,948,769
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halper Sadeh LLC is Investigating SKYT, EXAS, GORO, MOVE on Behalf of Shareholders

Today 15:05 EST

Shareholders should contact the firm as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

Today 14:32 EST

From Exact Sciences Corp.

Via Business Wire

Performance

YTD	+0.9%	+0.9%
1 Month	+1.0%	+1.0%
3 Month	+53.2%	+53.2%
6 Month	+119.1%	+119.1%
1 Year	+85.8%	+85.8%

More News

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (Nasdaq - NFBK), Coterra Energy Inc. (NYSE - CTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – SEMR)

Today 11:52 EST

From Brodsky & Smith LLC

Via GlobeNewswire

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

Today 9:03 EST

From Exact Sciences Corp.

Via Business Wire

Halper Sadeh LLC Reminds Shareholders of EXAS, DVN, NFBK of the Firm’s Investigations

February 02, 2026

From Halper Sadeh LLC

Via GlobeNewswire

The Best Dividend King to Buy With $150 ↗

February 02, 2026

Via The Motley Fool

Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race

February 02, 2026

Via MarketMinute

3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗

January 26, 2026

Via The Motley Fool

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Via MarketMinute

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

January 22, 2026

Via MarketMinute

Halper Sadeh LLC Encourages PEN, EXAS, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026

From Halper Sadeh LLC

Via GlobeNewswire

$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation

January 19, 2026

Via MarketMinute

Halper Sadeh LLC Encourages SEE, EXAS, ZEUS Shareholders to Contact the Firm to Discuss Their Rights

January 17, 2026

From Halper Sadeh LLC

Via GlobeNewswire

CS Diagnostics (OTCQB: CSDX) Advances Infection Control and Oncology Innovation Plus – IVP, SAFX, JTAI, OCG, BMXI Inside

January 14, 2026

Via AB Newswire

The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A

January 14, 2026

Via MarketMinute

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Via MarketMinute

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

Via MarketMinute

Halper Sadeh LLC Encourages EXAS, FRGE, TBHC, FFWM Shareholders to Contact the Firm to Discuss Their Rights

January 09, 2026

From Halper Sadeh LLC

Via GlobeNewswire

3 Mid-Cap Stocks We Steer Clear Of

January 08, 2026

Via StockStory

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

Via StockStory

3 Unpopular Stocks We Steer Clear Of

December 30, 2025

Via StockStory

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

December 11, 2025

From Exact Sciences Corp.

Via Business Wire

1 Healthcare Stock for Long-Term Investors and 2 We Avoid

December 10, 2025

Via StockStory

Frequently Asked Questions

Is Exact Sciences Corporation - Common Stock publicly traded?

Yes, Exact Sciences Corporation - Common Stock is publicly traded.

What exchange does Exact Sciences Corporation - Common Stock trade on?

Exact Sciences Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Exact Sciences Corporation - Common Stock?

The ticker symbol for Exact Sciences Corporation - Common Stock is EXAS on the Nasdaq Stock Market

What is the current price of Exact Sciences Corporation - Common Stock?

The current price of Exact Sciences Corporation - Common Stock is 102.61

When was Exact Sciences Corporation - Common Stock last traded?

The last trade of Exact Sciences Corporation - Common Stock was at 02/03/26 02:59 PM ET

What is the market capitalization of Exact Sciences Corporation - Common Stock?

The market capitalization of Exact Sciences Corporation - Common Stock is 17.64B

How many shares of Exact Sciences Corporation - Common Stock are outstanding?

Exact Sciences Corporation - Common Stock has 18B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.